Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes

The impact of somatostatin receptor type 2 (SSTR‐2a) expression levels on outcomes in patients with pancreatic neuroendocrine tumors (PNETs) has not been evaluated.

[1]  B. Wiedenmann,et al.  Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin , 2013, Neuroendocrinology.

[2]  H. Ueno,et al.  Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma , 2012, Neuroendocrinology.

[3]  N. Hamilton,et al.  Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. , 2012, Surgery.

[4]  M. Gadelha,et al.  Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: Comparison between quantitative real time RT-PCR and immunohistochemistry , 2012, Journal of Endocrinological Investigation.

[5]  T. Honma,et al.  Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry , 2012, Acta histochemica et cytochemica.

[6]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[7]  P. Nuciforo,et al.  Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine Tumors , 2011, Neuroendocrinology.

[8]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[9]  E. Krenning,et al.  Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. , 2010, Gastroenterology.

[10]  K. Nakao,et al.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan , 2010, Journal of Gastroenterology.

[11]  A. Scarpa,et al.  Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas , 2008, Neuroendocrinology.

[12]  M. Papotti,et al.  Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy , 2007, Modern Pathology.

[13]  E. T. Janson.  Treatment of neuroendocrine tumors with somatostatin analogs , 2006, Pituitary.

[14]  Jeffrey W. Clark,et al.  A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors , 2006, Digestive Diseases and Sciences.

[15]  G. Meno-Tetang,et al.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. , 2002, European journal of endocrinology.

[16]  R. Jian,et al.  The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors , 2000, American Journal of Gastroenterology.

[17]  J. Reubi,et al.  Somatostatin Receptors , 1997, Trends in Endocrinology & Metabolism.

[18]  L. Mariani,et al.  Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group , 1996, Cancer.

[19]  G. Bell,et al.  Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[21]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .